P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
ECCO '19 Copenhagen
2019
P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment
ECCO '19 Copenhagen
2019
P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
ECCO '19 Copenhagen
2019
P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
ECCO '19 Copenhagen
2019
P504: How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?
ECCO '19 Copenhagen
2019
P505: Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry
ECCO '19 Copenhagen
2019
P506: Steroid treatment for longer than 2 weeks leading to admission predicts higher colectomy rates in children with acute severe ulcerative colitis
ECCO '19 Copenhagen
2019
P507: Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis
ECCO '19 Copenhagen
2019
P508: Does corticosteroid therapy affect prognosis in inflammatory bowel disease patients hospitalised with Clostridium difficile infection?
ECCO '19 Copenhagen
2019
P509: Long-term outcomes of adalimumab in patients with Crohn’s disease: Can a doubled dose of adalimumab improve outcomes?
ECCO '19 Copenhagen
2019
P510: Infliximab in the very young: it is all about the dosing – a multi-centre study
ECCO '19 Copenhagen
2019
P512: Results of interim analysis of a retrospective IGIBD study on adalimumab use in real practice in Italy: the REAL-life clinical effectiveness of ADAlimumab in ulcerative colitis
ECCO '19 Copenhagen
2019
P513: Performance of a rapid test for adalimumab monitoring vs. conventional ELISA in a routine laboratory setting
ECCO '19 Copenhagen
2019
P514: Health Care Transition outcomes in inflammatory bowel disease: an international Delphi study
ECCO '19 Copenhagen
2019
P515: Costs associated with the management of refractory complex perianal fistulas in patients with Crohn's disease
ECCO '19 Copenhagen
2019
P516: The use of first-line biologics in patients with ulcerative colitis in Norway from 2011 to 2016
ECCO '19 Copenhagen
2019
P517: Activity assessment in ulcerative colitis: correlation analysis of endoscopic and histological scores
ECCO '19 Copenhagen
2019